Posted by Michael Wonder on 06 Feb 2023
Sandoz biologics license application for proposed biosimilar denosumab accepted by US FDA
6 February 2023 - Submission supported by comprehensive analytical and clinical data package.
Sandoz today announced that the US FDA has accepted its biologics license application for proposed biosimilar denosumab.
